184
O. D. Putra and H. Uekusa
71. Kumar, B.V.S., Kale, S.A., Choudhari, R.B., Pradhan, N.S.C.: Novel crystalline forms of
desloratadine and processes for their preparation. Patent US2007/0135472A1 (2006)
72. Ainurofiq, A., Mauludin, R., Mudhakir, D., Umeda, D., Soewandhi, S.N., Putra, O.D.,
Yonemochi, E.: Improving mechanical properties of desloratadine via multicomponent crystal
formation. Eur. J. Pharm. Sci. 111, 65–72 (2018)
73. Tao, W., Chen, J., Lu, T., Ma, L.: Phenazopyridine cocrystal and salts that exhibit enhanced
solubility and stability. Cryst. Growth Des. 12, 3144–3152 (2012)
74. Stanton, M.K., Bak, A.: Physicochemical properties of pharmaceutical co-crystals: a case study
of ten AMG 517 co-crystals. Cryst. Growth Des. 8, 3856–3862 (2008)
75. Putra, O.D., Yoshida, T., Umeda, D., Higashi, K., Uekusa, H., Yonemochi, E.: Crystal structure
determination of dimenhydrinate after more than 60 years: solving salt-cocrystal ambiguity via
solid-state characterizations and solubility study. Cryst. Growth Des. 16, 5223–5229 (2016)
76. He, H., Huang, Y., Zhang, Q., Wang, J., Mei, X.: Zwitterionic cocrystals of flavonoids
and proline: solid-state characterization, pharmaceutical properties, and pharmacokinetic
performance. Cryst. Growth Des. 16, 2348–2356 (2016)
77. Maeno, Y., Fukami, T., Kawahata, M., Yamaguchi, K., Tagami, T., Ozeki, T., Suzuki, T.,
Tomono, K.: Novel pharmaceutical cocrystal consisting of paracetamol and trimethylglycine,
a new promising cocrystal former. Int. J. Pharm. 473, 179–186 (2014)
78. Swapna, B., Nangia, A.: Epalrestat-cytosine cocrystal and salt structures: attempt to control
E,Z→Z,Z isomerization. Cryst. Growth Des. 17, 3350–3360 (2017)
79. Putra, O.D., Umeda, D., Nugraha, Y.P., Nango, K., Yonemochi, E., Uekusa, H.: Simultaneous
improvement of epalrestat photostability and solubility via cocrystallization: a case study.
Cryst. Growth Des. 18, 373–379 (2018)
80. Ohashi, Y., Tomotake, Y., Uchida, A., Sasada, Y.: Crystalline-state reaction of cobaloxime
complexes by X-ray exposure. 13. A stepwise structure analysis of the concerted process of
racemization. J. Am. Chem. Soc. 108, 1196–1202 (1986)
81. Couplands, J.N., Hayes, J.E.: Physical approaches to masking bitter taste: lessons from food
and pharmaceuticals. Pharm. Res. 31, 2921–2939 (2014)
82. Del Valle, E.M.M.: Cyclodextrins and their uses: a review. Process Biochem. 38, 1033–1046
(2004)
83. Thakral, S., Thakral, N.K., Majumdar, D.K.: Eudragit: a technology evaluation. Expert Opin.
Drug Deliv. 10, 131–149 (2013)
84. Wang, C., Hu, S., Sun, C.C.: Expedited development of a high dose orally disintegrating
metformin tablet enabled by sweet salt formation with acesulfame. Int. J. Pharm. 532, 435–443
(2017)
85. Iwasaki, T., Matsunaga, K.: Nitric oxide-associated vasorelaxing effect of an anti-ulcer agent,
benexate hydrochloride betadex. Drug. Dev. Res. 36, 13–19 (1995)
86. Hori, Y., Odaguchi, K., Jyoyama, H., Yasui, K., Mizui, T.: Differential effect of benexate
hydrochloride betadex on prostaglandin levels in stomach and inflammatory sites in rats. Jpn.
J. Pharmacol. 72, 183–190 (1996)
87. Muranushi, N., Yoshida, M., Kinoshita, H., Hirose, F., Fukuda, T., Doteuchi, M., Yamada, H.:
Studies of benexate CD: effect of inclusion compound formation on the antiulcer activity of
benexate, the effective ingredient of benexate CD. Folia Pharmacol. Jpn. 91, 377–383 (1988)
88. Banarjee, R., Bhatt, P.M., Ravindra, N.V., Desiraju, G.R.: Saccharin Salts of Active Pharmaceutical Ingredients, Their Crystal Structure, and Increased Water Solubilities. Cryst. Growth
Des. 5, 2299–2309 (2005)
89. Putra, O.D., Umeda, D., Fujita, E., Haraguchi, T., Uchida, T., Yonemochi, E., Uekusa, H.: Solubility improvement of benexate through salt formation using artificial sweetener. Pharmaceutics
10(64) (2018)
90. Cattopadhyay, S., Raychaudhuri, U., Chakraborty, R.: Artificial sweeteners—a review. J. Food
Sci. Technol. 51, 611–621 (2014)
O. D. Putra and H. Uekusa
71. Kumar, B.V.S., Kale, S.A., Choudhari, R.B., Pradhan, N.S.C.: Novel crystalline forms of
desloratadine and processes for their preparation. Patent US2007/0135472A1 (2006)
72. Ainurofiq, A., Mauludin, R., Mudhakir, D., Umeda, D., Soewandhi, S.N., Putra, O.D.,
Yonemochi, E.: Improving mechanical properties of desloratadine via multicomponent crystal
formation. Eur. J. Pharm. Sci. 111, 65–72 (2018)
73. Tao, W., Chen, J., Lu, T., Ma, L.: Phenazopyridine cocrystal and salts that exhibit enhanced
solubility and stability. Cryst. Growth Des. 12, 3144–3152 (2012)
74. Stanton, M.K., Bak, A.: Physicochemical properties of pharmaceutical co-crystals: a case study
of ten AMG 517 co-crystals. Cryst. Growth Des. 8, 3856–3862 (2008)
75. Putra, O.D., Yoshida, T., Umeda, D., Higashi, K., Uekusa, H., Yonemochi, E.: Crystal structure
determination of dimenhydrinate after more than 60 years: solving salt-cocrystal ambiguity via
solid-state characterizations and solubility study. Cryst. Growth Des. 16, 5223–5229 (2016)
76. He, H., Huang, Y., Zhang, Q., Wang, J., Mei, X.: Zwitterionic cocrystals of flavonoids
and proline: solid-state characterization, pharmaceutical properties, and pharmacokinetic
performance. Cryst. Growth Des. 16, 2348–2356 (2016)
77. Maeno, Y., Fukami, T., Kawahata, M., Yamaguchi, K., Tagami, T., Ozeki, T., Suzuki, T.,
Tomono, K.: Novel pharmaceutical cocrystal consisting of paracetamol and trimethylglycine,
a new promising cocrystal former. Int. J. Pharm. 473, 179–186 (2014)
78. Swapna, B., Nangia, A.: Epalrestat-cytosine cocrystal and salt structures: attempt to control
E,Z→Z,Z isomerization. Cryst. Growth Des. 17, 3350–3360 (2017)
79. Putra, O.D., Umeda, D., Nugraha, Y.P., Nango, K., Yonemochi, E., Uekusa, H.: Simultaneous
improvement of epalrestat photostability and solubility via cocrystallization: a case study.
Cryst. Growth Des. 18, 373–379 (2018)
80. Ohashi, Y., Tomotake, Y., Uchida, A., Sasada, Y.: Crystalline-state reaction of cobaloxime
complexes by X-ray exposure. 13. A stepwise structure analysis of the concerted process of
racemization. J. Am. Chem. Soc. 108, 1196–1202 (1986)
81. Couplands, J.N., Hayes, J.E.: Physical approaches to masking bitter taste: lessons from food
and pharmaceuticals. Pharm. Res. 31, 2921–2939 (2014)
82. Del Valle, E.M.M.: Cyclodextrins and their uses: a review. Process Biochem. 38, 1033–1046
(2004)
83. Thakral, S., Thakral, N.K., Majumdar, D.K.: Eudragit: a technology evaluation. Expert Opin.
Drug Deliv. 10, 131–149 (2013)
84. Wang, C., Hu, S., Sun, C.C.: Expedited development of a high dose orally disintegrating
metformin tablet enabled by sweet salt formation with acesulfame. Int. J. Pharm. 532, 435–443
(2017)
85. Iwasaki, T., Matsunaga, K.: Nitric oxide-associated vasorelaxing effect of an anti-ulcer agent,
benexate hydrochloride betadex. Drug. Dev. Res. 36, 13–19 (1995)
86. Hori, Y., Odaguchi, K., Jyoyama, H., Yasui, K., Mizui, T.: Differential effect of benexate
hydrochloride betadex on prostaglandin levels in stomach and inflammatory sites in rats. Jpn.
J. Pharmacol. 72, 183–190 (1996)
87. Muranushi, N., Yoshida, M., Kinoshita, H., Hirose, F., Fukuda, T., Doteuchi, M., Yamada, H.:
Studies of benexate CD: effect of inclusion compound formation on the antiulcer activity of
benexate, the effective ingredient of benexate CD. Folia Pharmacol. Jpn. 91, 377–383 (1988)
88. Banarjee, R., Bhatt, P.M., Ravindra, N.V., Desiraju, G.R.: Saccharin Salts of Active Pharmaceutical Ingredients, Their Crystal Structure, and Increased Water Solubilities. Cryst. Growth
Des. 5, 2299–2309 (2005)
89. Putra, O.D., Umeda, D., Fujita, E., Haraguchi, T., Uchida, T., Yonemochi, E., Uekusa, H.: Solubility improvement of benexate through salt formation using artificial sweetener. Pharmaceutics
10(64) (2018)
90. Cattopadhyay, S., Raychaudhuri, U., Chakraborty, R.: Artificial sweeteners—a review. J. Food
Sci. Technol. 51, 611–621 (2014)